US OptionsDetailed Quotes
AXSM240719P47500
- 0.00
- 0.000.00%
15min DelayTrading Jul 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest47.50Strike Price0.00Turnover5740.40%IV44.93%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.0949Delta0.0035Gamma--Leverage Ratio-114.7096Theta0.0000Rho0.00Eff Leverage0.0014Vega
Axsome Therapeutics Stock Discussion
Sign in to post a comment
$Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $Axsome Therapeutics(AXSM.US$ $Macrogenics(MGNX.US$
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
16
5
$Pfizer(PFE.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$ Phase 3
$Aquestive Therapeutics(AQST.US$ Phase 3
$Jaguar Health(JAGX.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$Johnson & Johnson(JNJ.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$ Phase 3
$Aquestive Therapeutics(AQST.US$ Phase 3
$Jaguar Health(JAGX.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$Johnson & Johnson(JNJ.US$ Phase 3
8
1
1. $Annovis Bio(ANVS.US$
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US$
• Ph 3 data (PATHFND...
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US$
• Ph 3 data (PATHFND...
7
🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
16
The strong revenue growth mirrors the robust share price gain. Top performers like Axsome Therapeutics can continue winning for decades. This seems like a good opportunity, despite the already positive sentiment.
$Pfizer(PFE.US$ Phase 3
$Regenxbio(RGNX.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Vertex Pharmaceuticals(VRTX.US$ Phase 3
$KalVista Pharmaceuticals(KALV.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$Applied Therapeutics(APLT.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3 ...
$Regenxbio(RGNX.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Vertex Pharmaceuticals(VRTX.US$ Phase 3
$KalVista Pharmaceuticals(KALV.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$Applied Therapeutics(APLT.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3 ...
20
1
Despite being loss-making, Axsome Therapeutics' strong cash position and revenue increase provide a positive outlook. It's projected to improve its free cash flow with further revenue growth.
Axsome Therapeutics' 66% projected growth rate may be overly optimistic. A slower growth rate might push the break-even point further, and the high debt level of 63% of its equity amplifies the investment risk in the unprofitable company.
Pre-Market Stock Movers
Gapping up
$Sagimet Biosciences(SGMT.US$
(Shares of the biopharmaceutical company popped 31% following an upgrade from Goldman Sachs. The firm highlighted Sagimet could see strong gains thanks to progress on a treatment for non-alcoholic steatohepatitis.）
$Eli Lilly and Co(LLY.US$
(The pharmaceutical stock climbed 8.6% after an earnings beat. The company reported an adjusted $2.11 per share ...
Gapping up
$Sagimet Biosciences(SGMT.US$
(Shares of the biopharmaceutical company popped 31% following an upgrade from Goldman Sachs. The firm highlighted Sagimet could see strong gains thanks to progress on a treatment for non-alcoholic steatohepatitis.）
$Eli Lilly and Co(LLY.US$
(The pharmaceutical stock climbed 8.6% after an earnings beat. The company reported an adjusted $2.11 per share ...
15
1
follow for daily top watchlist ⭐️
$Apyx Medical(APYX.US$ $Addentax(ATXG.US$ $Axsome Therapeutics(AXSM.US$ $BioXcel Therapeutics(BTAI.US$ $Baudax Bio(BXRX.US$ $CymaBay Therapeutics(CBAY.US$ $CorMedix(CRMD.US$ $Marriott International(MAR.US$ $Microvision(MVIS.US$ $Renalytix(RNLX.US$ $State Street(STT.US$ $Treehouse Foods(THS.US$ $Targa Resources(TRGP.US$ $VBI Vaccines(VBIV.US$ $Ventas Inc(VTR.US$
$Apyx Medical(APYX.US$ $Addentax(ATXG.US$ $Axsome Therapeutics(AXSM.US$ $BioXcel Therapeutics(BTAI.US$ $Baudax Bio(BXRX.US$ $CymaBay Therapeutics(CBAY.US$ $CorMedix(CRMD.US$ $Marriott International(MAR.US$ $Microvision(MVIS.US$ $Renalytix(RNLX.US$ $State Street(STT.US$ $Treehouse Foods(THS.US$ $Targa Resources(TRGP.US$ $VBI Vaccines(VBIV.US$ $Ventas Inc(VTR.US$
1
No comment yet
Salmon Klein : are you in $Macrogenics (MGNX.US)$ ? tell me when good to jump in
MangoXXXX Salmon Klein: Now
Meticulous Trader Salmon Klein: Do your own research , I think hovering in bottom and buy signal from pattern about to begin , do not follow me blindly my
Salmon Klein Meticulous Trader: I am waiting to reach 14.8 or so, but I am busy working, if it reached the bottom and you are in...any good feedback is always very welcomed bro...just that so thanks
Meticulous Trader Salmon Klein: Double higher bottom in intra-day might not hit below 14ish or if so still chance for 2 more trading sideways days, I am almost 25% down ( reason holding beyond top) anyway